Believing “good companies are bought, not sold” does not reflect the reality of most life sciences transactions, write ...

The bar for product differentiation and commercial viability has never been higher. Efficiency, external collaboration, and ...

Now is the time for leaders in Washington to act to protect patients, safeguard innovation, and strengthen our economy, ...

In this week's episode of the Business of Biotech -- part two in a four-part series recorded in-person at Catalyst Pharmaceuticals' Miami headquarters -- we're speaking with Daniel Teper, an ...

October is World Blindness Awareness Month, and patients with ultra-rare eye diseases are in desperate need of a new drug ...

For small and midsize radiopharmaceutical developers, an experienced commercial partner can make or break the success of new ...

Current trends in drug development point toward a growing number of therapies that are targeting smaller patient populations. As the batch sizes required to manufacture clinical and commercial supply ...

The Business of Biotech is on location in Miami this week! For the first episode in this four-part series on the biotech scene in South Florida, Raquel Cabo, Founder and President of the Miami Biotech ...

Over the years, I’ve had the privilege of working alongside some extraordinary leaders. When I reflect on those who have left the most lasting impact on me, I often describe them as having what I call ...

This article is the third and final installment of a three-part series aimed at helping drug and device manufacturers better navigate the VA and DoD health systems. Click here to read part one of the ...